Physician profile
Belmina N Michael
NPI 1063451458
$3,135.71
in general payments reported to CMS, 2019-2025
18 companies · $859 in 2025
The $859 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $70.30 · 2021: $196 · 2022: $384 · 2023: $490 · 2024: $842 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,174 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.25 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $924.81 | 2019-2025 | |
| Amgen INC. | $451.39 | 2020-2025 | Otezla, Otezla |
| Ucb, INC. | $308.70 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $192.58 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $187.84 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $184.32 | 2022-2025 | |
| Pfizer INC. | $156.67 | 2022-2025 | |
| Leo Pharma INC. | $150.32 | 2023-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $125.45 | 2024-2025 | |
| Urovant Sciences INC | $124.16 | 2022 | |
| Janssen Biotech, INC. | $74.16 | 2023-2025 | Stelara, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $74.07 | 2023-2024 | Libtayo |
| Celgene Corporation | $49.27 | 2019 | |
| Arcutis Biotherapeutics, INC. | $29.96 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.43 | 2025 | Spevigo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $28.65 | 2019 | |
| Merck Sharp & Dohme LLC | $28.03 | 2019 | |
| Galderma Laboratories, L.P. | $15.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Belmina Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.